Gut
Cure8 research brief
Why This Matters
Finding neutralising anti-IL-10 antibodies in a subset of children with IBD may help explain why some patients have more severe, treatment‑resistant disease and points to a potential biomarker for risk stratification.
Who Should Pay Attention
Pediatric IBD clinicians, researchers studying immune mechanisms or biomarkers in IBD, and parents/caregivers of children with difficult-to-treat IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This cross-sectional study screened serum/plasma from children with IBD for IgG autoantibodies that neutralise interleukin-10 (IL-10). Functional assays confirmed IL-10 neutralisation and linked the antibodies to amplified pro-inflammatory cytokine responses in vitro.
Patients positive for anti-IL-10 had worse clinical outcomes versus matched controls (higher prevalence of difficult-to-treat disease, more acute severe UC, and higher colectomy rates). Most tested anti-IL-10-positive patients carried the HLA-DRB1*01:03 allele, supporting a genetic association.
These findings suggest anti-IL-10 is a candidate biomarker identifying a small subgroup of paediatric IBD with more aggressive disease, but the study is cross-sectional and does not establish causality or inform specific treatment changes.
Keep In Mind
This is a multicentre cross-sectional study (abstract-level summary). The presence of antibodies was confirmed by functional assays, but the study design cannot prove the antibodies cause worse outcomes. Further work is needed to validate findings, determine prevalence in other cohorts, and explore clinical use of testing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationGut
AuthorsNima Gharahdaghi, Pai-Jui Yeh, Katherine Vadakethala +54 more
InstitutionCentre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 11, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Competing interests: None declared.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Genetic Marker Linked to Severe Outcomes Across IBD Subtypes - Medscape
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
Mechanisms and clinical outcomes linking HLA-DRB1*01:03 and IBD
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
Host-microbe Interactions in the Appendix of Children with Inflammatory Bowel Diseases.
Researchers found distinct microbial and host molecular features in the appendices of children with IBD, which could help explain local immune activation and guide future studies of disease mechanisms or biomarkers.